Search clinical trials for: AKR 202

Total 4514 results

Akron Molecules AG

Completed

A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain

Osteoarthritis

Austria
TScan Therapeutics, Inc.

Recruiting

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Melanoma | Cervical Cancer | Head and Neck Cancer | HPV-Related Malignancy | Ovarian Cancer | HPV-Related Carcinoma | HPV-Related Cervical Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Non-small Cell Carcinoma | HPV - Anogenital Human Papilloma Virus Infection | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma and other conditions

United States
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

Parkinson's Disease

Switzerland
Auregen Biotherapeutics, SA

Recruiting

Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201 (AUR-201)

Microtia

United States
Auregen Biotherapeutics, SA

Recruiting

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (AUR-201)

Microtia

United States
Auregen Biotherapeutics, SA

Enrolling by invitation

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia) (AUR-201)

Microtia

Australia
Atriva Therapeutics GmbH

Terminated

Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19 (RESPIRE)

COVID-19

Germany, India, Netherlands, Poland, Romania, South Africa, Spain
Hookipa Biotech GmbH

Recruiting

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

HPV-Related Squamous Cell Carcinoma

United States, Spain, Netherlands
Aerie Pharmaceuticals

Completed

Ocular Hypotensive Efficacy of AR-102

Glaucoma

United States
Atriva Therapeutics GmbH
SGS Life Sciences, a division of SGS Belgium NV

Completed

Phase 1 Study of ATR-002

Influenza

Belgium
ARYx Therapeutics

Completed

Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers

Atrial Fibrillation

United States, Canada
InQpharm Group

Completed

Efficacy and Safety of IQP-AK-102 in Reducing Appetite

Appetite Regulation | Energy Intake | Appetite Suppression

Germany
Celgene

Completed

Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

Healthy

United States
InQpharm Group

Completed

Safety and Efficacy of IQP- AK-102 in Reducing Body Weight

Weight Loss

Germany
InQpharm Group

Completed

Safety and Efficacy of IQP-AK-102 in Reducing Appetite

Weight Loss | Appetite Modulation (Focus of Study)

Germany
Baxter Healthcare Corporation
Gambro Renal Products, Inc.

Completed

Gambro AK200 ULTRA Hemodiafiltration Study

Chronic Renal Failure

United States
University Medicine Greifswald

Active, not recruiting

Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI) ((AIGI))

Seasonal Influenza Vaccination

Germany
Yusuf Menda
National Cancer Institute (NCI); National Institutes of Health (NIH); Holden...

Not yet recruiting

A Safety Study of 212Pb-Pentixather Radioligand Therapy

Carcinoid Tumor Lung | Neuroendocrine Tumor of the Lung | Carcinoma, Small-Cell Lung

United States
Trygg Pharma, Inc.

Unknown

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

Severe Hypertriglyceridemia

United States
Evofem Inc.
Neothetics, Inc

Terminated

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

Central Abdominal Bulging
Dartmouth-Hitchcock Medical Center
Vanderbilt University; University of Vermont

Completed

IMPROVE AKI Cluster-Randomized Trial (IMPROVE-AKI)

Acute Kidney Injury

United States
REGENXBIO Inc.

Recruiting

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States
Alpine Immune Sciences, Inc.

Terminated

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)

Lymphoma | Advanced Solid Tumor

United States, Australia
GenSpera, Inc.

Completed

Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme

United States
GenSpera, Inc.

Completed

Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Neothetics, Inc

Unknown

An Open-Label Study to Evaluate Retreatment With LIPO-202

Central Abdominal Bulging

United States
Sarang K. Yoon, DO, MOH
Novavax; Westat

Recruiting

The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection (BEEHIVE)

COVID-19 | SARS CoV 2 Infection | Vaccine-Preventable Diseases | Upper Respiratory Tract Infection | Upper Respiratory Disease

United States
McMaster University
Canadian Institutes of Health Research (CIHR)

Recruiting

Relative Impacts on Preventative Primary Care--a Longitudinal Evaluation of COVID-19:Phase 1 (RIPPLE-C)

Diabetes Mellitus | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Osteoarthritis | Dementia | Congestive Heart Failure | Depression, Anxiety

Canada
ILIAS Biologics Inc.

Completed

A Study to Evaluate the Safety and Tolerability of ILB-202

Healthy

Australia
Devalingam Mahalingam
GenSpera, Inc.

No longer available

Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
GenSpera, Inc.

Withdrawn

Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer.

United States
Immune-Onc Therapeutics
California Institute for Regenerative Medicine (CIRM)

Recruiting

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

CMML | AML With Monocytic Differentiation

United States
Oui Therapeutics, Inc.
National Institute of Mental Health (NIMH)

Enrolling by invitation

A Study to Evaluate the Safety and Effectiveness of a Digital Therapeutic

Suicidal Ideation | Suicide, Attempted

United States
GenSpera, Inc.
Saint John's Cancer Institute

Withdrawn

Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma

Glioblastoma

United States
Inversago Pharma Inc.

Active, not recruiting

Study of INV-202 in Patients With Obesity and Metabolic Syndrome

Obesity | Metabolic Syndrome

Canada
Inversago Pharma Inc.

Completed

A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome

Metabolic Syndrome

Canada
GenSpera, Inc.

Completed

Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA

Clear Cell Renal Cell Carcinoma

United States
GenSpera, Inc.

Completed

G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer

Prostatic Neoplasms

United States
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Centre Cardiologique du Nord
Universita degli Studi di Genova; Henri Mondor University Hospital; Pitié-Salpêtrière...

Enrolling by invitation

Outcomes of Type A Aortic Dissection Repair (STAAD)

Aortic Valve Insufficiency | Aortic Diseases | Ascending Aortic Dissection | Aortic Arch | Aortic Root Dissection | Aortic Root Dilatation | Type A Aortic Dissection

France
Arno Therapeutics

Unknown

Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Seoul National University Hospital

Completed

NuGa (Nutrition for Gastric Cancer Patients)

Gastric Cancer

Korea, Republic of
Bial - Portela C S.A.

Completed

Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202

Parkinson's Disease

United Kingdom
Canopy Growth Corporation

Completed

Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity

Delayed Onset Muscle Soreness (DOMS)

United States
Northwestern University
Brain & Behavior Research Foundation; Neurocentria, Inc.

Completed

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
Bial - Portela C S.A.

Completed

Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202

Parkinson's Disease

United Kingdom
Eisai Inc.

Completed

Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Idiopathic

United States
M.D. Anderson Cancer Center
Oncoceutics, Inc.

Recruiting

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
Immune-Onc Therapeutics

Active, not recruiting

Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Solid Tumor, Adult

United States

Search clinical trials for: AKR 202

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations